The April issue of Health Affairs is dedicated to Alzheimer’s. Authors gathered in Washington, D.C., to articulate how world policy could take shape.
A new bill asks Congress to ramp up Alzheimer’s funding by breaking down the cost to meet each of the milestones in the national plan. It appropriates no funds.
A new bill will centralize the approval process for multinational trials and mandate the publication of trial results—good or bad.
Allegations of scientist misconduct led to the retraction of one high-profile stem cell paper and put two others in doubt.
Nucleotide repeat expansions in the C9ORF72 gene occur in amyotrophic lateral sclerosis and frontotemporal dementia. Now researchers find the same repeats in patients with two other neurological disorders.
Tirasemtiv, a drug thought to make muscles more sensitive to signals from motor neurons, failed to improve muscle function in people with amyotrophic lateral sclerosis.
Scientists claim that AV-133, an imaging agent that visualizes dopaminergic neurons, can gauge progression of Parkinson’s disease.
Scientists generate human embryonic stem cell lines from adult donor cells, building on earlier studies that showed this was possible with fetal cells.
Marek-Marsel Mesulam received the prestigious award for his research on primary progressive aphasia, a language disorder that can affect people with Alzheimer’s or frontotemporal dementia.
It’s Not All About You, Neurons. Glia, Blood, Arteries Shine at Symposium Fluid Markers and Imaging Back Idea of Breached Blood-Brain Barrier In Revival of Parabiosis, Young Blood Rejuvenates Aging Microglia, Cognition Glymphatic Flow, Sleep, microRNA Are ...
By finding differences in gene expression between monocytes and T cells, scientists reveal that the innate immune system has strong ties to neurodegenerative disease.
European and U.S. agencies approve a third amyloid PET tracer, florbetaben.
Known for helping form new memories, new neurons may be just as important for erasing old ones.
Resveratrol consumption failed to correlate with heart disease, inflammation, cancer, or even mortality in a community-based study. Are its benefits overstated?
Will an antibody signature make for a new Alzheimer’s diagnostic?